These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 30840024)

  • 1. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.
    Mani P; Puri R; Schwartz GG; Nissen SE; Shao M; Kastelein JJP; Menon V; Lincoff AM; Nicholls SJ
    JAMA Cardiol; 2019 Apr; 4(4):314-320. PubMed ID: 30840024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
    Nicholls SJ; Kastelein JJ; Schwartz GG; Bash D; Rosenson RS; Cavender MA; Brennan DM; Koenig W; Jukema JW; Nambi V; Wright RS; Menon V; Lincoff AM; Nissen SE;
    JAMA; 2014 Jan; 311(3):252-62. PubMed ID: 24247616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.
    Rosenson RS; Hislop C; Elliott M; Stasiv Y; Goulder M; Waters D
    J Am Coll Cardiol; 2010 Sep; 56(14):1079-88. PubMed ID: 20863951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Lipoprotein(a) With Risk of Recurrent Ischemic Events Following Acute Coronary Syndrome: Analysis of the dal-Outcomes Randomized Clinical Trial.
    Schwartz GG; Ballantyne CM; Barter PJ; Kallend D; Leiter LA; Leitersdorf E; McMurray JJV; Nicholls SJ; Olsson AG; Shah PK; Tardif JC; Kittelson J
    JAMA Cardiol; 2018 Feb; 3(2):164-168. PubMed ID: 29071331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial.
    Bergmark BA; Udell JA; Morrow DA; Cannon CP; Steen DL; Jarolim P; Budaj A; Hamm C; Guo J; Im K; Kuder JF; Braunwald E; Sabatine MS; O'Donoghue ML
    JAMA Cardiol; 2018 Jun; 3(6):473-480. PubMed ID: 29710336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
    Bittner VA; Szarek M; Aylward PE; Bhatt DL; Diaz R; Edelberg JM; Fras Z; Goodman SG; Halvorsen S; Hanotin C; Harrington RA; Jukema JW; Loizeau V; Moriarty PM; Moryusef A; Pordy R; Roe MT; Sinnaeve P; Tsimikas S; Vogel R; White HD; Zahger D; Zeiher AM; Steg PG; Schwartz GG;
    J Am Coll Cardiol; 2020 Jan; 75(2):133-144. PubMed ID: 31948641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial.
    Fanola CL; Morrow DA; Cannon CP; Jarolim P; Lukas MA; Bode C; Hochman JS; Goodrich EL; Braunwald E; O'Donoghue ML
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29066436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.
    Hagström E; Roe MT; Hafley G; Neely ML; Sidhu MS; Winters KJ; Prabhakaran D; White HD; Armstrong PW; Fox KA; Ohman EM; Boden WE;
    Clin Cardiol; 2016 Jun; 39(6):329-37. PubMed ID: 27177240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial.
    Puri R; Nissen SE; Arsenault BJ; St John J; Riesmeyer JS; Ruotolo G; McErlean E; Menon V; Cho L; Wolski K; Lincoff AM; Nicholls SJ
    JAMA Cardiol; 2020 Oct; 5(10):1136-1143. PubMed ID: 32639518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
    Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The residual risk of inflammation and remnant cholesterol in acute coronary syndrome patients on statin treatment undergoing percutaneous coronary intervention.
    Liao J; Qiu M; Su X; Qi Z; Xu Y; Liu H; Xu K; Wang X; Li J; Li Y; Han Y
    Lipids Health Dis; 2024 Jun; 23(1):172. PubMed ID: 38849939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High high-sensitivity C-reactive protein/BMI ratio predicts future adverse outcomes in patients with acute coronary syndrome.
    Jia L; Yuan JQ; Zhu L; Zhang Y
    Coron Artery Dis; 2019 Sep; 30(6):448-454. PubMed ID: 31386638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial.
    Nicholls SJ; Nelson AJ; Lincoff AM; Brennan D; Ray KK; Cho L; Menon V; Li N; Bloedon L; Nissen SE
    JAMA Cardiol; 2024 Mar; 9(3):245-253. PubMed ID: 38231501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of high-density lipoprotein particle concentration with cardiovascular risk following acute coronary syndrome: A case-cohort analysis of the dal-Outcomes trial.
    Salahuddin T; Kittelson J; Tardif JC; Shah PK; Olsson AG; Nicholls SJ; Leitersdorf E; Leiter LA; Kallend D; Black DM; Barter PJ; Ballantyne CM; Schwartz GG
    Am Heart J; 2020 Mar; 221():60-66. PubMed ID: 31927126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial.
    Hwang YC; Morrow DA; Cannon CP; Liu Y; Bergenstal R; Heller S; Mehta C; Cushman W; Bakris GL; Zannad F; White WB
    Diabetes Obes Metab; 2018 Mar; 20(3):654-659. PubMed ID: 29064626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial.
    Nicholls SJ; Cavender MA; Kastelein JJ; Schwartz G; Waters DD; Rosenson RS; Bash D; Hislop C
    Cardiovasc Drugs Ther; 2012 Feb; 26(1):71-5. PubMed ID: 22109255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death.
    Scirica BM; Cannon CP; Sabatine MS; Jarolim P; Sloane S; Rifai N; Braunwald E; Morrow DA;
    Clin Chem; 2009 Feb; 55(2):265-73. PubMed ID: 19074516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-sensitivity C-reactive protein predicts adverse outcomes after non-ST-segment elevation acute coronary syndrome regardless of GRACE risk score, but not after ST-segment elevation myocardial infarction.
    Raposeiras Roubín S; Barreiro Pardal C; Roubín-Camiña F; Ocaranza Sanchez R; Alvarez Castro E; Paradela Dobarro B; García-Acuña JM; Aguiar Souto P; Jacquet Hervet M; Castromán MJ; Arufe I; Outes B; Reino-Maceiras MV; Abu Assi E; González-Juanatey JR
    Rev Port Cardiol; 2013 Feb; 32(2):117-22. PubMed ID: 23337430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal High-Sensitivity C-Reactive Protein and Longer-Term Cardiovascular Outcomes in Optimally-Treated Patients With High-Risk Vascular Disease.
    Dykun I; Clark D; Carlo J; Lincoff AM; Menon V; Nissen SE; Nicholls SJ; Puri R
    Am J Cardiol; 2022 Oct; 181():1-8. PubMed ID: 35970631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography.
    Cavusoglu E; Ruwende C; Chopra V; Yanamadala S; Eng C; Pinsky DJ; Marmur JD
    Coron Artery Dis; 2009 Mar; 20(2):112-7. PubMed ID: 19240644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.